Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) held its virtual annual meeting of shareholders on September 19, 2024. Shareholders elected all nominated directors and approved the appointment of PricewaterhouseCoopers LLP as auditors. The election results showed strong support for all nominees, with approval rates ranging from 98.66% to 99.02%. The directors elected include Ken d'Entremont, Harmony Garges, Benoit Gravel, Michael Mueller, Stephen Nelson, Nancy Phelan, and Menassie Taddese. The appointment of auditors received 99.32% approval. A detailed report of the voting results will be filed with Canadian securities regulatory authorities and will be available on www.sedarplus.com.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) ha tenuto la sua riunione annuale virtuale degli azionisti il 19 settembre 2024. Gli azionisti hanno eletto tutti i direttori nominati e approvato la nomina di PricewaterhouseCoopers LLP come revisori. I risultati delle elezioni hanno mostrato un forte supporto per tutti i candidati, con tassi di approvazione che variano da 98,66% a 99,02%. I direttori eletti includono Ken d'Entremont, Harmony Garges, Benoit Gravel, Michael Mueller, Stephen Nelson, Nancy Phelan e Menassie Taddese. La nomina dei revisori ha ricevuto un 99,32% di approvazione. Un rapporto dettagliato sui risultati delle votazioni sarà presentato alle autorità di regolamentazione dei titoli canadesi e sarà disponibile su www.sedarplus.com.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) celebró su reunión anual virtual de accionistas el 19 de septiembre de 2024. Los accionistas eligieron a todos los directores nominados y aprobaron la designación de PricewaterhouseCoopers LLP como auditores. Los resultados de la elección mostraron un fuerte apoyo para todos los postulantes, con tasas de aprobación que oscilan entre 98.66% y 99.02%. Los directores electos incluyen a Ken d'Entremont, Harmony Garges, Benoit Gravel, Michael Mueller, Stephen Nelson, Nancy Phelan y Menassie Taddese. La designación de auditores recibió un 99.32% de aprobación. Se presentará un informe detallado de los resultados de la votación a las autoridades regulatorias de valores canadienses y estará disponible en www.sedarplus.com.
메데쿠스 제약(Medexus Pharmaceuticals)(TSX: MDP)(OTCQX: MEDXF)는 2024년 9월 19일 가상 연례 주주총회를 개최했습니다. 주주들은 모든 지명된 이사를 선출했습니다 그리고 PricewaterhouseCoopers LLP를 감사인으로 임명하는 것에 대해 승인했습니다. 선거 결과는 모든 후보자에 대한 강력한 지지를 보여주었으며, 승인 비율은 98.66%에서 99.02% 사이였습니다. 선출된 이사들은 Ken d'Entremont, Harmony Garges, Benoit Gravel, Michael Mueller, Stephen Nelson, Nancy Phelan, 그리고 Menassie Taddese입니다. 감사인 임명은 99.32%의 승인을 받았습니다. 투표 결과에 대한 자세한 보고서는 캐나다 증권 규제 당국에 제출될 것이며 www.sedarplus.com에서 확인할 수 있습니다.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) a tenu sa réunion annuelle virtuelle des actionnaires le 19 septembre 2024. Les actionnaires ont élu tous les administrateurs nommés et approuvé la nomination de PricewaterhouseCoopers LLP en tant qu'auditeurs. Les résultats des élections ont montré un fort soutien pour tous les candidats, avec des taux d'approbation allant de 98,66 % à 99,02 %. Les administrateurs élus incluent Ken d'Entremont, Harmony Garges, Benoit Gravel, Michael Mueller, Stephen Nelson, Nancy Phelan et Menassie Taddese. La nomination des auditeurs a reçu une approbation de 99,32 %. Un rapport détaillé des résultats de vote sera déposé auprès des autorités réglementaires canadiennes et sera disponible sur www.sedarplus.com.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) hielt am 19. September 2024 die virtuelle Jahreshauptversammlung der Aktionäre ab. Die Aktionäre wählten alle nominierten Direktoren und genehmigten die Ernennung von PricewaterhouseCoopers LLP als Prüfer. Die Wahlergebnisse zeigten eine starke Unterstützung für alle Kandidaten, mit Zustimmungsraten von 98,66 % bis 99,02 %. Zu den gewählten Direktoren gehören Ken d'Entremont, Harmony Garges, Benoit Gravel, Michael Mueller, Stephen Nelson, Nancy Phelan und Menassie Taddese. Die Ernennung der Prüfer erhielt eine 99,32 %ige Zustimmung. Ein detaillierter Bericht über die Wahlergebnisse wird bei den kanadischen Wertpapieraufsichtsbehörden eingereicht und auf www.sedarplus.com verfügbar sein.
- High shareholder approval rates for all director nominees (98.66% to 99.02%)
- Strong support for the appointment of PricewaterhouseCoopers LLP as auditors (99.32% approval)
- None.
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 7, 2024 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors.
Detailed voting results for the election of directors are set out in the table below.
| Name | For | Against |
| Ken d'Entremont | ||
| Harmony Garges | ||
| Benoit Gravel | ||
| Michael Mueller | ||
| Stephen Nelson | ||
| Nancy Phelan | ||
| Menassie Taddese |
Shareholders also cast 8,922,492 (
A report of the voting results on all matters voted on at the annual meeting will be filed with Canadian securities regulatory authorities at www.sedarplus.com.
About Medexus
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.
Contacts
Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com
Forward-Looking statements
Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws, also known and/or referred to as "forward-looking information" or "forward-looking statements". The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on regulatory guidelines, historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that, although the assumptions are believed to be reasonable in the circumstances, these risks and uncertainties mean that actual results could differ, and could differ materially, from the expectations contemplated by the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223941
FAQ
When did Medexus Pharmaceuticals (MEDXF) hold its annual meeting of shareholders?
Who were elected as directors for Medexus Pharmaceuticals (MEDXF) in the 2024 annual meeting?
What was the approval rate for the appointment of auditors for Medexus Pharmaceuticals (MEDXF)?
Where can investors find the detailed voting results for Medexus Pharmaceuticals' (MEDXF) 2024 annual meeting?
